Assessment of chronic myeloid leukemia patients' adherence with “tyrosine kinase inhibitors” in King Abdulaziz Medical City

CONTEXT: Worldwide, chronic myeloid leukemia (CML) accounts for 15% of all leukemia types. CML treatment and outcome has improved dramatically from the average survival of 3–5 years in the past to almost normal life expectancy with the new targeted therapy with tyrosine kinase inhibitors (TKI). Comp...

Descrición completa

Detalles Bibliográficos

Principais autores:	Saad Saleh Aldughaythir, Yousef Alolah, Mohsen Alzahrani, Fahad Abdulaziz Alsayed, Bader Muaykil Alqahtani, Omar Abdulrahman Alhathlol
Formato:	Artigo
Idioma:	Inglês
Publicado:	Wolters Kluwer Medknow Publications 2017-01-01
Series:	Journal of Applied Hematology
Assuntos:	Chronic myeloid leukemia compliance tyrosine kinase inhibitors
Acceso en liña:	http://www.jahjournal.org/article.asp?issn=1658-5127;year=2017;volume=8;issue=4;spage=140;epage=144;aulast=Aldughaythir
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!